Kyrgyzstan Medical Device Variation Management: Dossier Amendments and Re-Registration Boundary

1. Key takeaways

Every amendment of a registration dossier in Kyrgyzstan must be reviewed and approved by the competent authority; there is no notification-only procedure under which a change takes effect upon reporting. Any change, whether to the manufacturer name, the manufacturing site, the model list, or the labeling, or a change of authorized representative, goes through a change application (Annex 2 of the public forms of the competent authority) and, after review, is reflected on the registration certificate. The practical implication of this rule is that companies cannot act first and report later, and there is no category of minor change exempt from filing.

2. Legal basis

1. Cabinet Resolution No. 513, August 27, 2024, Annex 1, Article 1: the procedure governs amendments of the registration dossier, maintenance of the national register, and suspension and revocation of registration certificates.
2. Public forms of the competent authority, Annex 2: application form for amendments of the registration dossier.
3. Law No. 216, Article 14: the obligation to report changes to device data and information rests with the manufacturer or its authorized representative.
4. Protocol amending the Agreement of 2014-12-23 (2025-12-29): the deadline for handling re-registration and registration dossier amendments under the national rules of member states is 2028-12-31.
5. Multilateral country research report (Japan International Cooperation Agency, November 2025): when a model changes or is improved, a re-registration application must be submitted; components not listed at initial registration must be registered separately.

3. Expert insights

Insight 1: change and re-registration are two different routes, and the boundary must be drawn early.

The multilateral country research states expressly that when a model undergoes a change or improvement, a re-registration application must be submitted. This means variation management has a watershed:

• Change procedure: informational changes, such as name, address, site, authorized representative, and labeling elements;
• Re-registration: changes or improvements to the product itself, such as new models, design modifications, or software feature changes.

Misclassify the watershed, and the price is being told to resubmit after taking the wrong procedure.

Insight 2: the transition period sets a hard endpoint for the change procedure.

The Protocol of 2025-12-29 sets December 31, 2028 as the deadline for handling re-registration and registration dossier amendments under national rules. This is the single most important date for change management in this market: after it, any dossier change can only be handled under Union rules. Combined with the unlimited validity of registration certificates under Article 15, this creates an unusual state: the certificate never expires, but after 2028 the dossier is effectively frozen, and every change requires migration.

Insight 3: the duty to report changes falls on the manufacturer or its authorized representative, but internal division is not specified.

Article 14 places the obligation on both parties in joint terms. If the agreement does not say who actually performs it, both sides will blame the other when a change goes unreported, while the competent authority looks only at the record on the certificate. We recommend designating the performing party in the agreement and setting an internal trigger mechanism (see Part 08 of this series).

Insight 4: a backlog of changes is the most realistic risk of the transition period.

Product iterations, site adjustments, and replacements of the authorized representative keep generating change needs. If they are not processed in bulk during the transition period, every single one after 2029 must go through the Union track. We recommend completing a full dossier review of all products within 2027 and submitting all known change needs in a concentrated batch (see Part 12 of this series).

Insight 5: old packaging and instructions of marketed products are usually allowed to sell through expiry.

After a change is approved, products made under the old labeling and instructions may still be on the market. We recommend confirming the transition arrangement for already marketed products within the change application, to avoid a deadlock in which the new dossier is approved but old stock cannot be sold. This point is subject to the reply of the competent authority.

4. Practical recommendations

First, build a change decision tree: classify the route before preparing materials. We recommend a three-step test: does the change affect the function, design, or intended use of the product itself? If yes, assess re-registration. Is it an informational change? If yes, use the change procedure. Does it affect the risk class or the GMDN type? If yes, redo the classification rationale and then proceed by change or re-registration.

Second, process known changes in a concentrated batch within the transition period. We recommend completing a full dossier review of all products within 2027, submitting in one batch the four categories of model additions, site changes, authorized representative replacements, and labeling updates, and closing them all before 2028-12-31.

Third, designate the performing party for changes in the agreement. We recommend specifying that the authorized representative handles submission, the manufacturer supplies the technical documents and supporting materials, and response deadlines are agreed.

Fourth, confirm transition arrangements for marketed products within the change application. We recommend asking the competent authority within the application about the sell-through period for old labeling and instructions, and executing per the reply.

Fifth, keep a change ledger linked to registration dossier versions. We recommend a change ledger for each product line recording the change item, application date, approval date, and certificate update status, managed together with the dossier status ledger described in Part 08 of this series.

5. Verification checklist

• □ A change decision tree has been established, distinguishing the change procedure from re-registration;
• □ A full dossier review of all products was completed within 2027, with known change needs closed before 2028-12-31;
• □ The agreement designates the performing party for changes and sets response deadlines;
• □ Change applications use the current published Annex 2 form of the competent authority;
• □ The change application confirms the transition arrangement for old labeling and instructions of marketed products;
• □ A change ledger has been established and is managed in linkage with the dossier status ledger.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance coaching, post-market surveillance and vigilance system setup, import and distribution compliance, state fee estimation, and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. It maintains a stable local cooperation network in Bishkek, Almaty, Tashkent, Moscow, and other cities, and works in Chinese, Russian, and English. For the key issues that foreign manufacturers commonly face in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection response, GRZAN provides executable solutions.

We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources. Any figure or timeline that cannot be verified is always labeled as a practical estimate, and experience values are never presented as legal grounds.

GRZAN provides registration and compliance support in Kyrgyzstan for medical device manufacturers, importers, and authorized representatives. For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services